Myocardial contrast echocardiography in humans: I. Safety - a comparison with routine coronary arteriography

C. A. Moore, M. L. Smucker, Sanjiv Kaul

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Myocardial contrast echocardiography is a new diagnostic cardiovascular imaging technique capable of defining perfusion zones of coronary vessels in vivo; ultimately, it may be used to measure absolute regional myocardial blood flow. However, before it can be used in humans, its safety must be clearly established. Accordingly, the electrocardiographic and hemodynamic effects of intracoronary injections of 2 cc of sonicated Renografin-76 were compared with 5 to 10 cc of nonsonicated Renografin-76 in 10 subjects with normal coronary arteries. Two cubic centimeters of sonicated Renografin provides optimal myocardial opacification during echocardiography, while 5 to 10 cc of Renografin is required for an adequate coronary arteriogram. During coronary arteriography, heart rate decreased while PR and QT intervals and QRS duration increased as compared with baseline and myocardial contrast echocardiography (p <0.01). Similarly, the decrease in aortic pressure and first derivative of left ventricular pressure (dP/dT) was significantly (p <0.01) greater during routine coronary arteriography than during myocardial contrast echocardiography. Changes in left ventricular end-diastolic or pulmonary capillary wedge pressure were similar during myocardial contrast echocardiography and coronary angiography. There were no significant differences in the duration of electrocardiographic and hemodynamic changes between myocardial contrast echocardiography and coronary arteriography. It is concluded that intracoronary injection of 2 cc of sonicated Renografin-76 provides optimal myocardial opacification. It is safe in humans, producing transient electrocardiographic and hemodynamic alterations that are less pronounced than those seen during routine coronary angiography.

Original languageEnglish (US)
Pages (from-to)1066-1072
Number of pages7
JournalJournal of the American College of Cardiology
Volume8
Issue number5
StatePublished - 1986
Externally publishedYes

Fingerprint

Echocardiography
Angiography
Safety
Diatrizoate Meglumine
Hemodynamics
Coronary Angiography
Coronary Vessels
Injections
Pulmonary Wedge Pressure
Regional Blood Flow
Ventricular Pressure
Diagnostic Imaging
Arterial Pressure
Perfusion
Heart Rate
urovision

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Myocardial contrast echocardiography in humans : I. Safety - a comparison with routine coronary arteriography. / Moore, C. A.; Smucker, M. L.; Kaul, Sanjiv.

In: Journal of the American College of Cardiology, Vol. 8, No. 5, 1986, p. 1066-1072.

Research output: Contribution to journalArticle

@article{700129a619be4f10b9fb97cc8a0ca7b6,
title = "Myocardial contrast echocardiography in humans: I. Safety - a comparison with routine coronary arteriography",
abstract = "Myocardial contrast echocardiography is a new diagnostic cardiovascular imaging technique capable of defining perfusion zones of coronary vessels in vivo; ultimately, it may be used to measure absolute regional myocardial blood flow. However, before it can be used in humans, its safety must be clearly established. Accordingly, the electrocardiographic and hemodynamic effects of intracoronary injections of 2 cc of sonicated Renografin-76 were compared with 5 to 10 cc of nonsonicated Renografin-76 in 10 subjects with normal coronary arteries. Two cubic centimeters of sonicated Renografin provides optimal myocardial opacification during echocardiography, while 5 to 10 cc of Renografin is required for an adequate coronary arteriogram. During coronary arteriography, heart rate decreased while PR and QT intervals and QRS duration increased as compared with baseline and myocardial contrast echocardiography (p <0.01). Similarly, the decrease in aortic pressure and first derivative of left ventricular pressure (dP/dT) was significantly (p <0.01) greater during routine coronary arteriography than during myocardial contrast echocardiography. Changes in left ventricular end-diastolic or pulmonary capillary wedge pressure were similar during myocardial contrast echocardiography and coronary angiography. There were no significant differences in the duration of electrocardiographic and hemodynamic changes between myocardial contrast echocardiography and coronary arteriography. It is concluded that intracoronary injection of 2 cc of sonicated Renografin-76 provides optimal myocardial opacification. It is safe in humans, producing transient electrocardiographic and hemodynamic alterations that are less pronounced than those seen during routine coronary angiography.",
author = "Moore, {C. A.} and Smucker, {M. L.} and Sanjiv Kaul",
year = "1986",
language = "English (US)",
volume = "8",
pages = "1066--1072",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Myocardial contrast echocardiography in humans

T2 - I. Safety - a comparison with routine coronary arteriography

AU - Moore, C. A.

AU - Smucker, M. L.

AU - Kaul, Sanjiv

PY - 1986

Y1 - 1986

N2 - Myocardial contrast echocardiography is a new diagnostic cardiovascular imaging technique capable of defining perfusion zones of coronary vessels in vivo; ultimately, it may be used to measure absolute regional myocardial blood flow. However, before it can be used in humans, its safety must be clearly established. Accordingly, the electrocardiographic and hemodynamic effects of intracoronary injections of 2 cc of sonicated Renografin-76 were compared with 5 to 10 cc of nonsonicated Renografin-76 in 10 subjects with normal coronary arteries. Two cubic centimeters of sonicated Renografin provides optimal myocardial opacification during echocardiography, while 5 to 10 cc of Renografin is required for an adequate coronary arteriogram. During coronary arteriography, heart rate decreased while PR and QT intervals and QRS duration increased as compared with baseline and myocardial contrast echocardiography (p <0.01). Similarly, the decrease in aortic pressure and first derivative of left ventricular pressure (dP/dT) was significantly (p <0.01) greater during routine coronary arteriography than during myocardial contrast echocardiography. Changes in left ventricular end-diastolic or pulmonary capillary wedge pressure were similar during myocardial contrast echocardiography and coronary angiography. There were no significant differences in the duration of electrocardiographic and hemodynamic changes between myocardial contrast echocardiography and coronary arteriography. It is concluded that intracoronary injection of 2 cc of sonicated Renografin-76 provides optimal myocardial opacification. It is safe in humans, producing transient electrocardiographic and hemodynamic alterations that are less pronounced than those seen during routine coronary angiography.

AB - Myocardial contrast echocardiography is a new diagnostic cardiovascular imaging technique capable of defining perfusion zones of coronary vessels in vivo; ultimately, it may be used to measure absolute regional myocardial blood flow. However, before it can be used in humans, its safety must be clearly established. Accordingly, the electrocardiographic and hemodynamic effects of intracoronary injections of 2 cc of sonicated Renografin-76 were compared with 5 to 10 cc of nonsonicated Renografin-76 in 10 subjects with normal coronary arteries. Two cubic centimeters of sonicated Renografin provides optimal myocardial opacification during echocardiography, while 5 to 10 cc of Renografin is required for an adequate coronary arteriogram. During coronary arteriography, heart rate decreased while PR and QT intervals and QRS duration increased as compared with baseline and myocardial contrast echocardiography (p <0.01). Similarly, the decrease in aortic pressure and first derivative of left ventricular pressure (dP/dT) was significantly (p <0.01) greater during routine coronary arteriography than during myocardial contrast echocardiography. Changes in left ventricular end-diastolic or pulmonary capillary wedge pressure were similar during myocardial contrast echocardiography and coronary angiography. There were no significant differences in the duration of electrocardiographic and hemodynamic changes between myocardial contrast echocardiography and coronary arteriography. It is concluded that intracoronary injection of 2 cc of sonicated Renografin-76 provides optimal myocardial opacification. It is safe in humans, producing transient electrocardiographic and hemodynamic alterations that are less pronounced than those seen during routine coronary angiography.

UR - http://www.scopus.com/inward/record.url?scp=0022527348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022527348&partnerID=8YFLogxK

M3 - Article

C2 - 3760381

AN - SCOPUS:0022527348

VL - 8

SP - 1066

EP - 1072

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -